CV Sciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CV Sciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $20.05M | Apr 4, 2022 |
| FY2021 | Dec 31, 2020 | $24.43M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $53.70M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $48.24M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $20.68M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $11.06M | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $11.53M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $10.19M | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $2.15M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $0 | Mar 28, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.79M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.71M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $16.00M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $16.21M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $20.05M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $24.43M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $53.70M | Mar 19, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.75M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.17M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.09M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.55M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $8.62M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.01M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $35.09M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $33.88M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $14.49M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $7.00M | Mar 30, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($958.0K) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.39M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.10M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($8.21M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($15.55M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($22.28M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($16.61M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $10.00M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.90M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($14.14M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($470.0K) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.19M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.36M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($6.85M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($18.45M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($22.59M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($17.24M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $10.25M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.86M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($13.07M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $118.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $151.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $307.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.19M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.94M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $5.88M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.89M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $724.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.16M | Mar 30, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.62M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.24M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $9.75M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $12.09M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | $25.88M | Apr 4, 2022 |
| FY2021 | Dec 31, 2020 | $30.66M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $46.45M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $21.75M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $16.19M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $13.13M | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($407.0K) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($861.0K) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.25M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.89M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($7.49M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.30M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($2.23M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $12.56M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.62M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($2.05M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $35.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.06M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $1.15M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $893.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $454.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $17.2K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.96M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.93M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $9.20M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $12.74M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $18.07M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $30.63M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $52.69M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $36.90M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $22.71M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $18.59M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.13M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.30M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.51M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $14.52M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $19.41M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $23.54M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $6.79M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.33M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $5.38M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.80M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.90M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | ($777.0K) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.54M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $11.21M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $29.15M | Apr 4, 2022 |
| FY2020 | Dec 31, 2018 | $30.12M | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $16.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $13.21M | Mar 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $971.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $342.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Mar 27, 2025 |
| FY2022 | Dec 31, 2021 | $0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.79M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $2.79M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $2.79M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.79M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $2.79M | Mar 30, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($87.94M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($86.98M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($84.59M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($87.69M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($79.48M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($63.92M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($41.64M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($25.03M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($35.03M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($30.13M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $611.0K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $1.38M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.02M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $9.11M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $12.68M | Mar 30, 2020 |
| FY2014 | Dec 31, 2014 | $2.30M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $2.24M | Mar 31, 2015 |
| FY2014 | Dec 31, 2012 | $431 | Mar 31, 2015 |
| FY2013 | Dec 31, 2011 | $1.2K | Mar 28, 2014 |
| FY2012 | Dec 31, 2010 | $30.7K | Apr 16, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.65M | Mar 26, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 4, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 12, 2019 |
| FY2015 | Dec 31, 2015 | 0 | Apr 14, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 4, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 12, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 184.26M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 184.26M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 161.68M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 152.10M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 112.48M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 100.66M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | 99.42M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | 94.94M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 90.51M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 57.62M | Mar 30, 2018 |